Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Emblem Corp. Launches Leading Line of Cannabis Oils to Meet Growing Demand and Drive Patient Acquisition


Posted on: 18 Dec 17

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

TORONTO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC) (EMC.WT) (“Emblem” or the “Company”), one of the country’s leading licensed producers, is pleased to announce the launch today of four cannabis oils that can now be ordered online or by phone from its award-winning customer service team.

The four oils being launched are: 20:0 THC Indica, 20:0 THC Sativa, 12:20 THC/CBD, 0:20 THC/CBD (the numbers representing the milligrams per milliliter of THC and CBD, two of the primary cannabinoids in the cannabis plant). Each are packaged with an oral syringe to ensure consistency and accuracy in measuring exactly how much oil is ingested, allowing patients to better titrate and administer each dose the exact same way.

“Today is an important milestone for Emblem,” says Nick Dean, CEO of Emblem Corp. “With sales of cannabis oil now growing at a faster rate than dried flower in Canada, patients are clearly demonstrating a preference to move away from vapor or smoke. It also makes dosing more accessible and allows for a consistent delivery system.”

Used to treat a variety of conditions and ailments, cannabis oils help with a broad spectrum of health problems and allows for consistent, standardized dosing that produces a specific effect each time.

“We are particularly excited by our CBD oils,” says Dean. “CBD is not psychoactive, and a recent report from the World Health Organization suggests CBD to be an effective treatment for epileptic seizures, amongst a number of other medical conditions. Physicians are increasingly turning to CBD-rich strains for their patients.”

Emblem Corp. is already a leader on the medical side with its patient and physician vertical known as GrowWise Health. With 14 education centres in Canada and plans to expand in the coming months, the GrowWise brand is already synonymous with patient and physician education.

“Patients and healthcare professionals will turn to Emblem as a reliable source for medication. The availability of Emblem oils will help to drive our medical strategy and allow us to onboard patients at a more rapid pace and see strong top-line growth. We continue to invest in pharmaceutical research and development, and will be bringing more medically-focused products to market in the coming year,” says Dean.

Patients registered with Emblem will be entitled to 10% off their first oil purchase.

About Emblem

Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on Toronto Venture Exchange (TSXV).

Forward-looking statements

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (together, "forward-looking statements"). All statements and information contained herein that is not clearly historical in nature may constitute forward-looking statement. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company's annual information form dated October 18, 2017 which has been filed with the Canadian Securities Administrators and is available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Ali Mahdavi
Vice President, Capital Markets and Investor Relations
Emblem Corp.
(416) 962-3300
alimahdavi@emblemcorp.com 

GlobeNewswire
globenewswire.com

Last updated on: 19/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.